Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators; n engl j med; - DOI:
doi.org/10.1056/NEJMoa2103417 Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators; n engl j med; - DOI:
doi.org/10.1056/NEJMoa2105911 Ewa A. Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, Javed Butler, Stefan D. Anker et al;
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study: European Heart Journal, ehab234, - DOI:
doi.org/10.1093/eurheartj/ehab234Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, Theresa McDonagh, Maria Dorobantu, Jarosław Drozdz, Vincent Fabien, Gerasimos Filippatos, Udo Michael Göhring, Andre Keren, Irakli Khintibidze, Hans Kragten, Felipe A Martinez, Marco Metra, Davor Milicic, José C Nicolau, Marcus Ohlsson, Alexander Parkhomenko, Domingo A Pascual-Figal, Frank Ruschitzka, David Sim, Hadi Skouri, Peter van der Meer, Basil S Lewis, Josep Comin-Colet, Stephan von Haehling, Alain Cohen-Solal, Nicolas Danchin, Wolfram Doehner, Henry J Dargie, Michael Motro, Javed Butler, Tim Friede, Klaus H Jensen, Stuart Pocock, Ewa A Jankowska, on behalf of the
AFFIRM-AHF investigators Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial, The Lancet Published Online November 13, 2020, - DOI:
doi.org/10.1016/S0140-6736(20)32339-4Brett L Houston, Patrick R Lawler, Ewan C Goligher, Michael E Farkouh, Charlotte Bradbury, Marc Carrier, Vlad Dzavik, Dean A Fergusson, Robert A Fowler, Jean-Phillippe Galanaud, Peter L Gross, Emily G McDonald, Mansoor Husain, Susan R Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S Slutsky, Alexis F Turgeon, Scott M Berry, Robert S Rosenson, Jorge Escobedo, Jose C Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski; Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial; Clin Trials 2020 Oct; 17 (5):491-500
Friedrich Koehler, Kerstin Koehler, Sandra Prescher, Bridget-Anne Kirwan, Karl Wegscheider et al;
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial;
www.thelancet.com/digital-health Vol 2 January 2020
Piotr Ponikowski, Bridget-Anne Kirwan, Stefan D. Anker, Maria Dorobantu et al;
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferriccarboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure; European Journal of Heart Failure (2019)21, 1651–1658 STUDY DESIGN - DOI:
doi.org/10.1002/ejhf.1710Prof Friedrich Koehler, MD , Kerstin Koehler, MD, Oliver Deckwart, MScN, Sandra Prescher, MSc, Prof Karl Wegscheider, PhD, Bridget-Anne Kirwan, PhD, Sebastian Winkler, MD, Eik Vettorazzi, MSc, Leonhard Bruch, MD, Michael Oeff, MD, Christian Zugck, MD, Gesine Doerr, MD., Herbert Naegele, MD,Prof Stefan Störk, MD, Prof Christian Butter, MD, Prof Udo Sechtem, MD, Prof Christiane Angermann, MD, Guntram Gola, MD, Roland Prondzinsky, MD, Prof Frank Edelmann, MD, Sebastian Spethmann, MD, Prof Sebastian M Schellong, MD, Prof P Christian Schulze, MD, Prof Johann Bauersachs, MD, Brunhilde Wellge, MD, Christoph Schoebel, MD, Milos Tajsic, MD, Henryk Dreger, MD, Prof Stefan D Anker, MD, Prof Karl Stangl, MD;
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial; August 25, 2018 Lancet - DOI:
doi.org/10.1016/S0140-6736(18)31880-4Friedrich Koehler, Kerstin Koehler, Oliver Deckwart, Sandra Prescher, Karl Wegscheider; Sebastian Winkler; Eik Vettorazzi; Andreas Polze; Karl Stangl, Oliver Hartmann; Almuth Marx; Petra Neuhaus, Michael Scherf, Bridget-Anne Kirwan Stefan D. Anker:
Telemedical Interventional Management in Heart Failure II (TIM-HF 2), a randomized, controlled trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design and description of the intervention.–
doi.org/10.1002/ejhf.1300 – volume 10, Issue 10, October 2018
Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ,Ponikowski P.
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018 Jan;20(1):125-133.
doi.org/10.1002/ejhf.823,
Chiquet C, Aptel F, Creuzot-Garcher C, Berrod JP, Kodjikian L, Massin P, Deloche C, Perino J, Kirwan BA, de Brouwer S, Combette JM, Behar-Cohen;
Post-operative ocular inflammation: A single sub-conjunctival injection of XG-102 compared to dexamethasone drops in a randomized trial F. Am J Ophthalmol. 2016 Oct 31. pii: S0002-9394(16)30525-6.
doi: 10.1016/j.ajo.2016.10.012. PMID: 27810317
P. Barton Duell, Raul D. Santos, Bridget-Anne Kirwan, Joseph L. Witztum, Sotirios Tsimikas, John J.P. Kastelein:
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia; Journal of Clinical Lipidology; doi:
http://dx.doi.org/10.1016/j.jaci.2016.04.013Douglas L. Mann, Randall J. Lee, Andrew J.S. Coats, Gheorghe Neagoe4, Dinu Dragomir, Enrico Pusineri, Massimo Piredda, Luca Bettari, Bridget-Anne Kirwan, Robert Dowling, Maurizio Volterrani, Scott D. Solomon, Hani N. Sabbah, Andy Hinson, and Stefan D. Anker:
One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure; European Journal of Heart Failure 2015 European Society of Cardiology
doi:10.1002/ejhf.449Stefan D. Anker, Andrew J.S. Coats, Gabriel Cristian, Dinu Dragomir, Enrico Pusineri, Massimo Piredda, Luca Bettari, Robert Dowling, Maurizio Volterrani, Bridget-Anne Kirwan, Gerasimos Filippatos, Jean-Louis Mas, Nicolas Danchin, Scott D. Solomon, Randall J.Lee, Frank Ahmann, Andy Hinson, Hani N. Sabbah and Douglas L. Mann
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial) European Heart Journal,
doi:10.1093/eurheartj/ehv259Talal Beydoun, Catherine Deloche, Julien Perino, Bridget-Anne Kirwan, Jean-Marc Combette, Francine Behar-Cohen; A Safety and Tolerability Study. J Ocul Pharmacol Ther March 2015;31:93-9.
Andrew J Stewart Coats, Venkatesan Srinivasan, Jayaraman Surendran, Haritha Chiramana, Shankar R.K.G. Vangipuram, Nirajkumar Navinchandra Bhatt, Minish Jain, Sandip Shah, Irfhan Ali Bin Hyder Ali, Ho Gwo Fuang, Mohammed Zailani Mat Hassan, John Beadle Julia Tilson, Bridget-Anne Kirwan, Stefan D. Anker on behalf of the ACT-ONE Trial Investigators: The ACT-ONE TRIAL, a multicentre randomized, double-blind placebo-controlled dose finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design J cachexia Sarcopenia Muscle 2011 Dec, 2(4):201-207. Epub 2011 Oct 16
Friedrich Koehler, MD, Sebastian Winkler, MD, Michael Schieber, MD Udo Sechtem, MD, Karl Stangl, MD, Michael Böhm, MD, Sophie de Brouwer, PhD, Emilie Perrin, Gert Baumann, MD, Goetz Gelbrich, PhD, Herbert Boll, MD, Marcus Honold, MD, Kerstin Koehler, MD, Bridget-Anne Kirwan, PhD, Stefan D Anker, MD, PhD, on behalf of the TIM-HF Investigators: Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial - Int. J. Cardiol. 161, 143 (2012)
Friedrich Koehler, MD; Sebastian Winkler, MD; Michael Schieber, MD; Udo Sechtem, MD; Karl Stangl, MD; Michael Bohm, MD; Herbert Boll, MD; Gert Baumann, MD; Marcus Honold, MD; Kerstin Koehler, MD; Goetz Gelbrich, PhD; Bridget-Anne Kirwan, PhD; Stefan D. Anker, MD, PhD: Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure The Telemedical Interventional Monitoring in Heart Failure Study: Circulation, 2011 May 3; 123 (17):1873-80
Zoltán Vokó, MD, PhD; Sophie de Brouwer, PhD; Jacobus Lubsen, MD, PhD; Nicolas Danchin, MD;Jan-Erik Otterstad, MD; Peter HJM Dunselman MD, PhD; Bridget-Anne Kirwan, PhD: Long-term impact of secondary preventive treatments in patients with stable angina. European Journal of Epidemiology: 02/2011;26 (5):375-83
Friedrich Koehler, MD, Sebastian Winkler, MD, Michael Schieber, MD, Udo Sechtem, MD, Karl Stangl, MD, Michael Böhm, MD, Herbert Boll, MD, Simone S Kim, MD, Kerstin Koehler, MD, Stephanie Lücke, Markus Honold, MD, Peter Heinze, Thomas Schweizer, Martin Braecklein, Bridget-Anne Kirwan, PhD, Goetz Gelbrich, PhD, Stefan D Anker, MD PhD: Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design – European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2010; 12(12): 1354-62
Bonnie Ky, MD, Bridget-Anne Kirwan, PhD; Sophie de Brouwer, PhD, Jacobus Lubsen, MD, PhD, Philip Poole-Wilson, MD, Jan-Erik Otterstad, MD Stephen E. Kimmel, MD; Martin St. John Sutton, MBBS: Gender Differences in Cardiac Remodeling and Clinical Outcomes in Chronic Stable Angina Patients (from the ACTION trial): The American journal of cardiology 2010; 105(7): 943-7
Stefan D. Anker, M.D., Ph.D., Josep Comin Colet, M.D., Gerasimos Filippatos, M.D., Ronnie Willenheimer, M.D.,Kenneth Dickstein, M.D., Ph.D., Helmut Drexler, M.D., Thomas F. Lüscher, M.D., Boris Bart, M.D., Waldemar Banasiak, M.D., Ph.D.,Joanna Niegowska, M.D., Bridget-Anne Kirwan, Ph.D., Claudio Mori, M.D.,Barbara von Eisenhart Rothe, M.D., Stuart J. Pocock, Ph.D., Philip A. Poole-Wilson, M.D., Piotr Ponikowski, M.D., Ph.D.,for the FAIR-HF Trial Investigators: Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361: 2436-48
Faiez Zannad, Wendy Gattis Stough, Bertram Pitt, John G.F. Cleland, Kirkwood F. Adams, Nancy L. Geller, Christian Torp-Pedersen, Bridget-Anne Kirwan, and Ferenc Follath: Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur. Heart J., February 2008; 29(3): 413-421
Bridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, Frederik J. van Dalen, Stuart J. Pocock, Tim Clayton, Nicolas Danchin, Philip A. Poole-Wilson, on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators: Quality management of a large randomized double-blind multi-centre trial: The ACTION experience: Contemp. Clin Trials. 2008 Mar; 29(2) 29 259-269
Zoltán Vokó; Nocolas Danchin; Sophie de Brouwer; Bridget-Anne Kirwan; Philip A Poole-Wilson; Jacobus Lubsen: Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: the ACTION experience: Int J Cardiol 2008 Oct 7.
Kirwan B-A, Lubsen J, de Brouwer S, Danchin N, Dunselman P, Sutton G, Battler A, Bayes de Luna A, Glasser S, Koudstaal P, van Dalen F, Poole-Wilson PA. Diagnostic Criteria and adjudication process both determine published event rates: The ACTION trial experience. Contemp Clin Trials 2007 Nov; 28(6): 720-729
Motro M, Kirwan B-A, de Brouwer S, Poole-Wilson PA, Shemesh J on behalf of the ACTION CC side-arm study. Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy: Cardiology.2007; 107(3): 165-71
AM Dart, JE Otterstad, BA Kirwan, JD Parker, S de Brouwer, PA Poole-Wilson, J Lubsen, and ACTION investigators: Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study. Eur J Echocardiogr. 2007 Aug; 8(4): 275-83
Sutton GC, Otterstad JE, Kirwan B-A, Vokó Z, de Brouwer S, Lubsen J, Poole-Wilson PA on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. The development of heart failure in patients with stable angina pectoris. Eur J Heart Fail. 2007; 107(3): 165-71
Poole-Wilson PA, Kirwan B-A, Vokó Z, de Brouwer S, Dunselman P, van Dalen F, Lubsen J on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Resource utilization implications of treatment was assessed when clinical trial data are reported appropriately: J Clin Epidemiol. 2007 Jul; 60(7): 720-6
Lubsen J, Voko Z, Poole-Wilson PA, Kirwan B-A, de Brouwer S on behalf of the ACTION (A Coronary diseaseTrial Investigating Outcome with Nifedipine GITS) investigators. Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions: J Clin Epidemiol.2007 Jul; 60(7): 720-6
Ruilope LM, Kirwan B-A, de Brouwer S, Danchin N, Fox KA, Wagener G, Segura J, Poole-Wilson PA, Lubsen J on behalf of the ACTION investigators. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007 Aug; 25(8): 1711-1718
Poole-Wilson PA, Voko Z, Kirwan B-A, de Brouwer S, Dunselman P, Lubsen J for the ACTION investigators. Clinical course of isolated stable angina due to coronary heart disease: Eur Heart J. 2007 Aug; 28(16): 1928-35
Otterstad JE, Kirwan B-A, Lubsen J, de Brouwer S, Fox KA, Corell P, Poole-Wilson PA on behalf of the action investigators. Incidence and outcome of atrial fibrillation in stable symptomatic Coronary disease: Scand Cardiovasc J. 2006 Jun; 40(3): 152-9
Poole-Wilson PA, Kirwan B-A, Vokó Z, de Brouwer S, van Dalen F, Lubsen F. Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs ther. 2006 Feb; 20(1): 45-54
B-A Kirwan, J Lubsen, PA Poole-Wilson, on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators: Treatment of angina pectoris: associations with symptom severity. Int J Cardiol. 2005 Feb 15; 98(2): 299-306
Lubsen J, Wagener G, Kirwan B-A, de Brouwer S, Poole-Wilson PA on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005 Mar; 23(3): 641-8
J Shemesh, N Koren-Morag, S Apter, J Rozenman, B-A Kirwan, Y Itzchak, M Motro: Accelerated Progression of Coronary Calcification: Four-year follow-up in Patients with Stable Coronary Artery Disease: Radiology 2004; 233: 201-209
Poole-Wilson PA, Lubsen J, Kirwan, BA et al on behalf of the ACTION investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial: Lancet 2004; Sep 4-10; 364 (99437): 849-57
Tim C Clayton, Jacobus Lubsen, Stuart J Pocock, Zoltán Vokó, Bridget-Anne Kirwan, Keith A A Fox, Philip A Poole-Wilson, on behalf of the ACTION investigators: Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients: BMJ 2001; 323: 75-81
Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan B-A, Parker AB – Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS: Eur Heart J 1998 Aug:19 (suppl 1): 120-132
JE Otterstad, J Lubsen, A Parker, Kirwan B-A, Ted Plappert, Martin G St John Sutton: Left Ventricular Remodelling in Post –myocardial Infarction patients with Left Ventricular Ejection Fraction 40-50% vs 25-39%: Influence of nisoldipine treatment?: Scand Cardiovasc J 1999 33; 234-241
Lubsen J, Kirwan B-A. Combined end-points: Can we use them? (Statist. Med. 2002; 21: 2959-2970).